Celsense

 

 

NEWS RELEASE - For Immediate Release

Publication in Cell Transplantation Indicates That Cell Sense Does Not Affect Differentiation In Vivo

August 31, 2012 - Pittsburgh, Pennsylvania

Celsense, Inc. announced today the publication in the peer-reviewed scientific journal, Cell Transplantation, of an article that describes the results of a preclinical study evaluating the use of Cell Sense to label hematopoietic stem cells. Cell Sense, a perfluorocarbon tracer agent (PFC), is used to track the migration and persistence of transplanted cells in magnetic resonance imaging (MRI). The article, authored by investigators at Celsense and Case Western Reserve University, describes results demonstrating that Cell Sense-labeled hematopoietic stem cells retain their multipotency and ability to reconstitute both the lymphoid and myeloid cell populations following transfer after myeloablation.

“The routine use of Cell Sense to track the migration and persistence of transplanted cells in the clinic is dependent upon evidence that the MRI label does not affect the properties of the cell product in vivo. Using various in vitro assays, other investigations had previously demonstrated that the PFC cell label did not alter cell phenotype, proliferation, or ability to differentiate. As far as we can tell, this is the first study to demonstrate that multipotent cells labeled with a tracer agent retained their ability to differentiate in vivo,” said Dr. Amy Wesa, Director of Research and Development at Celsense, Inc.

The complexities of administering therapeutic cells were revealed in pilot imaging study of therapeutic stem cells. The authors reported that when delivered within a scaffold designed to retain cells at the site of implantation, the transplanted cells were easily detected and remained at the delivery point. Cells diluted into a saline solution and administered by needle into the muscle rapidly dispersed from the site of injection, with only a small fraction remaining. While cautioning that the study was preliminary, Dr. Wesa noted that the rapid disappearance of cells from the intra-muscular injection site was entirely unexpected, and that “it underscores the need to visualize the delivery of cellular products to avoid attributing a lack of intrinsic efficacy to a cellular therapeutic when the true problem is delivery to (or retention in) the target site.”

The abstract is now indexed in PubMed (http://www.ncbi.nlm.nih.gov/pubmed/22862925) and a link to the full text, pre-print of the published manuscript is available at  http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0489helfer

About Cell Sense
Cell Sense is a patented perfluorocarbon tracer agent used to label cells ex vivo, making them detectable in vivo after transplantation using magnetic resonance imaging (MRI).  Cell Sense can be used to non-invasively image the administration, migration, and persistence of cells transplanted for therapeutic or diagnostic purposes using MRI.

Cell Sense is currently available for use in preclinical research and human clinical trials. The first clinical use of Cell Sense is in combination with an autologous dendritic cell vaccine used to treat colorectal cancer; the trial was authorized by the U.S. FDA in May of 2011. It is contemplated that patient recruitment will commence in the summer of 2012.

About Celsense, Inc.
Celsense, Inc. develops and markets novel products that enable the non-invasive imaging of populations of cells in vivo using MRI. Customers include leading pharmaceutical and biotechnology companies as well as medical research centers worldwide. Celsense’s mission is to be the standard for cellular imaging in human health.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412)263-2870
charlie@celsense.com